New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.
BMI OrganBank™ Selected by the North Carolina Biotechnology Center for Funding to Advance Medical Device
NOTE: BMI OrganBank licensed perfusion tech from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig (Surgery, SOM).
Sparta Biomedical Recognized with the MedTech Innovator Execution Award and the AdvaMed Accel Virginia Shimer Rybski Memorial Award
Duke start-up Sparta Biomedical wins industry awards from both AdvaMed and MedTech Innovator.
Gilhuly Accelerator Fund Invests Over $1M in Duke Inventor Projects in its Inaugural Year
The Duke community, led by Trustee Ned Gilhuly, is supporting Duke inventors with its newest translational fund dedicated to accelerating the development of early-stage technologies with high commercial potential.
Watch: Translation & Commercialization as a collaborative, creative process
OTC licensing managers are creative partners to Duke inventors – just ask pathologist Dr. Soman Abraham and OTC’s Dr. Dennis Thomas.
MedTech Innovator Announces 2023 Grand Prize Finalists
Duke start-up Sparta Biomedical has been selected as one of five AdvaMed Accel and MedTech Innovator Execution Award Finalists.
Setting Rivalries Aside, University Startups Come Together to Pitch 50+ Elite Investors at Triangle Venture Day: Therapeutics 2023
The recurring event offers venture capital investors from across the country an exclusive look at therapeutics startups launching from Duke, UNC, NC State University, and the North Carolina Biotechnology Center.
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
ORSERDU is based on technology licensed out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).
Durham-based Restor3d raises $17 million
restor3d, a Duke spinout from the lab of Prof Ken Gall (MEMS, Pratt), is also a Duke Capital Partners portfolio company.